FDA Flags AI Overreliance
- The U.S. Food and Drug Administration issued an April 2 warning letter to Purolea Cosmetics Lab, saying the Michigan drug maker improperly relied on artificial intelligence to draft required manufacturing records and procedures. - FDA said Purolea’s quality unit failed to adequately review AI-generated specifications, procedures and master production records, and the firm said it missed process-validation requirements because its AI tool did not flag them. - The letter appears to be FDA’s first drug-manufacturing warning letter to explicitly fault AI use under current good manufacturing practice rules, signaling closer scrutiny of AI governance in regulated production. (dlapiper.com)
The Food and Drug Administration told Purolea Cosmetics Lab it cannot treat artificial intelligence like a substitute for its quality unit. (fda.gov) (raps.org) The warning letter was issued April 2, 2026 and posted April 14, 2026. FDA listed the Livonia, Michigan company under CGMP, finished pharmaceuticals, adulterated, and unapproved new drug violations. (fda.gov) Drug manufacturing runs on written instructions, batch records, specifications and release checks that are supposed to prove each lot was made the same way every time. FDA said Purolea used AI to generate some of those core records without adequate review by authorized quality personnel. (dlapiper.com) (raps.org) DLA Piper said the letter is the first time FDA has cited a drug manufacturer for improper reliance on AI in carrying out current good manufacturing practice obligations. The firm said FDA tied the problem to 21 CFR 211.22(c), which makes the quality unit responsible for approving or rejecting procedures and specifications. (dlapiper.com) FDA also tied the case to 21 CFR 211.100, which requires written production and process controls designed to ensure a drug’s identity, strength, quality and purity. According to DLA Piper and RAPS, investigators found Purolea had distributed drug products without required process validation. (dlapiper.com) (raps.org) When investigators asked about that gap, the firm said it was unaware of the validation requirement because the AI agent did not identify it. FDA’s response, as quoted by RAPS, was that AI-generated documents still had to be reviewed to ensure they were accurate and compliant. (raps.org) (dlapiper.com) RAPS reported that Purolea makes homeopathic drug products including Dermveda Extra Strength Shingles Relief and Dermveda Extra Strength Ultra Genital Herpes Relief. The same report said FDA also cited unsanitary conditions, including insects, dirt, leaves and clutter in parts of the facility. (raps.org) The letter does not ban AI in manufacturing. It says the company still needed traceable review, documented approvals and a functioning quality system run by people with authority to reject bad records and stop bad product. (dlapiper.com) For drug makers, the message in this case is narrower than “don’t use AI” and broader than one Michigan facility. FDA used an ordinary enforcement tool to say ordinary manufacturing duties still apply when the paperwork is drafted by a machine. (fda.gov) (dlapiper.com)
